HR-Positive/HER2-Negative Early Breast Cancer: Emerging Endocrine Strategies and the Potential Role of Giredestrant

Dr. Adam Brufsky and the panel shift their focus to early-stage HR-positive/HER2-negative breast cancer and discuss emerging endocrine therapy strategies that may influence future treatment paradigms. Dr. Rita Nanda, Dr. Rebecca Shatsky, and Dr. Virginia Kaklamani review recently presented data evaluating giredestrant in patients with early breast cancer and examine its potential role alongside established endocrine therapies and adjuvant CDK4/6 inhibitor-based approaches. The discussion explores key considerations surrounding treatment adherence, tolerability, patient-reported outcomes, and quality of life, particularly in patients who experience challenges with long-term aromatase inhibitor therapy. The faculty highlight the importance of maintaining effective endocrine treatment over extended periods and discuss how improved tolerability could influence adherence and clinical outcomes. The panel also considers potential future sequencing strategies, including the use of next-generation endocrine therapies in higher-risk patient populations, while emphasizing the need for additional clinical data to define optimal implementation. Throughout the conversation, the experts examine how emerging therapies may further personalize treatment for patients with HR-positive/HER2-negative early breast cancer.